查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
重症肌无力治疗市场，按药物类别、按年龄层、按配销通路、按国家和地区划分 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1388792

重症肌无力治疗市场，按药物类别、按年龄层、按配销通路、按国家和地区划分 - 2023-2030 年行业分析、市场规模、市场份额和预测

Myasthenia Gravis Treatment Market, By Drug Class, By Age Group, By Distribution Channel, By Country, and By Region -Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年重症肌无力治疗市场规模为201,243万美元，2023年至2030年复合CAGR为9.4%。

重症肌无力 (MG) 是一种慢性、罕见、进行性神经肌肉疾病，会导致头部、眼睛、四肢、脊椎和呼吸肌无力。这些自体免疫疾病中会产生针对乙酰胆碱受体 (AchR) 的抗体，阻止从神经到肌肉的正常电讯号传递。此外，颜面神经麻痹、眼睑下垂、复视和行走困难也是重症肌无力的症状。这些疾病可透过多种测试来诊断，包括抗体血液检查、磁振造影 (MRI)、依酚铵测试、重复神经刺激测试和电脑断层扫描 (CT)。

重症肌无力治疗市场-市场动态

全球重症肌无力盛行率的上升和人们对重症肌无力的认识的提高推动了市场的成长

全球重症肌无力发病率的上升、重症肌无力创新治疗方法的采用以及早期诊断知识的增加是推动重症肌无力治疗市场发展的主要驱动力。此外，製药公司越来越关注疾病治疗新药的开发，重症肌无力治疗市场也出现了显着成长。此外，正在测试和开发各种药物，包括免疫抑制剂和单株抗体，以了解其治疗重症肌无力的功效。然而，与用于治疗重症肌无力的药物相关的副作用预计将很快抑制市场成长。此外，医疗保健专业人员和患者对重症肌无力的认识不断提高，这在很大程度上促进了对有效治疗的需求的增加。与此一致的是，随着越来越多的人意识到重症肌无力的症状和风险，人们更有可能寻求重症肌无力的治疗和诊断。医疗保健专业人员对这种疾病及其可用治疗方法的了解也越来越多，导致对有效治疗的需求增加。

重症肌无力治疗市场 - 关键见解

  • 根据我们的研究分析师分享的分析，预计全球重症肌无力治疗市场在预测期内（2023-2030 年）每年将以 9.4% 左右的CAGR增长
  • 由于医疗保健专业人员和患者对重症肌无力的认识不断提高，重症肌无力治疗行业预计将以显着的速度增长
  • 根据药物类别细分，预计单株抗体将在 2022 年显示最大的市场份额
  • 从配销通路细分来看，医院药局是2022年的主导类型

政府提高重症肌无力意识和改善医疗基础设施的措施正在推动市场成长。

重症肌无力治疗市场-細項分析：

全球重症肌无力治疗市场依据药物类别、年龄层、配销通路和地区进行细分。

根据药物类别，市场分为五类：胸腺切除术、单株抗体、胆碱酯酶抑制剂、快速免疫疗法、慢性免疫调节剂等。由于治疗重症肌无力的精度高且疗效提高，单株抗体领域预计将占据最高的市场份额。越来越多地使用单株抗体旨在减少终生接触皮质类固醇并改善长期结果。

根据分销管道，市场分为三类：药局和零售药局、医院药局和线上提供者。医院药房部门可能会在预测期内保持其主导地位。该细分市场归因于对先进设备的高需求以及医院环境中用于 MG 治疗的大量患者库。此外，此类设施提供广泛的治疗选择，增加了接受治疗和诊断的患者就诊次数。对最先进的医疗基础设施的投资不断增加是其占据巨大份额的主要因素。

重症肌无力治疗市场 - 地理洞察

从地理上看，该市场分为北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步细分。北美在重症肌无力治疗方面拥有最大的市场份额。自体免疫疾病评估的成长、提供创新药物的重要公司的存在、重症肌无力的高发病率以及改善的医疗基础设施的可及性都预计将推动重症肌无力治疗产业的发展。此外，由于有关自体免疫疾病和可用治疗方案的认识活动的增加、自体免疫疾病数量的增加以及对开发重症肌无力有效治疗方案的投资增加，亚太地区的增长预计将显着。此外，在新兴经济体中，医疗保健支出的激增预计将为市场扩张提供利润丰厚的机会，从而推动重症肌无力治疗市场的发展。

重症肌无力治疗市场-竞争格局：

政府等一些组织正在为个人提供有关自体免疫疾病的咨询。由于与传统购买方式相比，消费者对网上购物的偏好增加，电子商务已成为全球大大小小的企业的重要工具。此外，一些透过健康应用程式来教育人们有关药物使用和重症肌无力的动画也促进了重症肌无力治疗市场的成长。此外，主要市场参与者已采取策略联盟、收购、产品核准、扩张和协议作为关键发展策略，以增强重症肌无力治疗产业的产品组合。例如，2021 年 3 月，致力于改善全世界人民健康和福祉的全球医疗保健公司 Grifols 宣布收购 GigaGen Inc.，以推动产生多种免疫球蛋白的新方法。

最近的发展：

例如，2023 年 4 月，全球生技公司 CSL Behring 的 Hizentra 50mL/10gm 预充式註射器获得 FDA 核准。 CSL Behring 提供各种尺寸的预充式註射器，以满足原发性免疫缺陷和慢性发炎性脱髓鞘性多发性神经病变患者的特定需求。

目录

第一章：重症肌无力治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的重症肌无力治疗市场片段
    • 按年龄组别分類的重症肌无力治疗市场片段
    • 按配销通路的重症肌无力治疗市场片段
    • 按国家/地区分類的重症肌无力治疗市场片段
    • 按地区分類的重症肌无力治疗市场片段
  • 竞争洞察

第 3 章：重症肌无力治疗主要市场趋势

  • 重症肌无力治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 重症肌无力治疗市场限制
    • 市场限制影响分析
  • 重症肌无力治疗市场机会
  • 重症肌无力治疗市场未来趋势

第 4 章：重症肌无力治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：重症肌无力治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：重症肌无力治疗市场格局

  • 2022 年重症肌无力治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：重症肌无力治疗市场 - 依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 胸腺切除术
    • 单株抗体
    • 胆碱酯酶抑制剂
    • 快速免疫疗法
    • 慢性免疫调节剂
    • 其他的

第 8 章：重症肌无力治疗市场 - 按年龄组

  • 概述
    • 按年龄组别分類的细分市场占有率分析
    • 55岁以下
    • 55岁以上

第 9 章：重症肌无力治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 药局和零售药局
    • 医院药房
    • 线上提供者

第 10 章：重症肌无力治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美重症肌无力治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按年龄组）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲重症肌无力治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按年龄层）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区重症肌无力治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（依年龄层）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲重症肌无力治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按年龄层）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲重症肌无力治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按年龄层）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 重症肌无力治疗产业

  • 竞争仪表板
  • 公司简介
    • F.Hoffmann-La Roche AG
    • Alexion Pharmaceutical Inc.
    • Zydus Lifesciences Limited
    • Grifols SA
    • Shire plc
    • Kedrion
    • Avadel Pharmaceuticals, Plc.
    • Octapharma AG
    • Novartis
    • Bausch Health Companies Inc.
    • Pfizer, Inc.
    • AbbVie Inc.
    • GlaxoSmithKline Plc.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1846

REPORT HIGHLIGHT

Myasthenia gravis treatment market size was valued at USD 2,012.43 Million in 2022, expanding at a CAGR of 9.4% from 2023 to 2030.

Myasthenia gravis (MG) is a type of chronic, rare, and progressive neuromuscular disorder that causes weakness of the head, eye, limb, spinal, and respiratory muscles. Antibodies against the acetylcholine receptor (AchR) that prevent proper electrical signal transmission from nerves to muscles are produced in these autoimmune disorders. Additionally, facial paralysis, drooping of eyelids, double vision, and difficulty in walking are symptoms of myasthenia gravis. These diseases are diagnosed by numerous tests including blood tests for antibodies, Magnetic Resonance Imaging (MRI), edrophonium test, repetitive nerve stimulation test, and Computed Tomography (CT).

Myasthenia Gravis Treatment Market- Market Dynamics

Rising prevalence and increasing awareness about myasthenia gravis worldwide driving the market growth

The rising global incidence of myasthenia gravis, the adoption of innovative treatments for myasthenia gravis, and increased knowledge about early diagnosis are the primary drivers driving the development of the myasthenia gravis treatment market. Moreover, the growing focus of pharmaceutical companies on the development of novel drugs for disease treatment is witnessing significant growth in the myasthenia gravis treatment market. Additionally, various medications, including immunosuppressants and monoclonal antibodies, are being tested and developed for their efficacy in treating myasthenia gravis. However, side effects associated with the drugs used for treating myasthenia gravis are expected to restrain the market growth shortly. Furthermore, rising awareness about myasthenia gravis among healthcare professionals and patients is majorly contributing to the increase in demand for effective treatments. In line with this, individuals are more likely to seek treatment and diagnosis for myasthenia gravis as more people become aware of its signs and risks. Healthcare professionals are also becoming more knowledgeable about the disease and its available treatments, leading to an increased demand for efficient treatments.

Myasthenia Gravis Treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global myasthenia gravis treatment market is estimated to grow annually at a CAGR of around 9.4% over the forecast period (2023-2030)
  • The myasthenia gravis treatment industry is projected to grow at a significant rate due to the rising awareness about myasthenia gravis among healthcare professionals and patients
  • Based on drug class segmentation, monoclonal antibodies was predicted to show maximum market share in the year 2022
  • Based on distribution channel segmentation, hospital pharmacies was the leading type in 2022

Government initiatives to increase consciousness regarding myasthenia gravis and improve healthcare infrastructure are fueling the market growth.

Myasthenia Gravis Treatment Market- Segmentation Analysis:

The global myasthenia gravis treatment market is segmented on the basis of drug class, age group, distribution channel, and region.

The market is divided into five categories based on drug class: thymectomy, monoclonal antibodies, cholinesterase inhibitors, rapid immunotherapies, chronic immunomodulators, and others. The monoclonal antibodies segment is expected to hold the highest market share due to the high precision in treating myasthenia gravis and improved efficacy. The rising use of monoclonal antibodies aims to reduce lifelong exposure to corticosteroids and improve long-term results.

The market is divided into three categories based on distribution channels: drugstore and retail pharmacies, hospital pharmacies, and online providers. The hospital pharmacies segment is likely to maintain its dominance over the forecast period. The segment is attributed to access to the high demand for advanced equipment and a large patient pool for MG treatment in hospital settings. Additionally, the availability of a broad range of treatment options in such facilities has increased patient visits for treatment and diagnosis. The rising investment in state-of-the-art healthcare infrastructures is the prime factor contributing to its large share.

Myasthenia Gravis Treatment Market- Geographical Insights

Geographically, this market is analyzed into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented as per the nations bringing business. North America has the biggest market share for myasthenia gravis therapy. The growth in autoimmune disease evaluation, the existence of significant companies providing innovative medicines, the high incidence of myasthenia gravis, and the accessibility of improved healthcare infrastructure are all expected to drive the myasthenia gravis treatment industry. Moreover, Asia-Pacific is accounted to witness notable growth due to the increase in awareness campaigns regarding autoimmune diseases & available treatment options, rising number of autoimmune diseases, and rising investments for the development of effective treatment options for myasthenia gravis. In addition, in emerging economies upsurge in healthcare expenditure is anticipated to provide lucrative opportunities for market expansion, driving the myasthenia gravis treatment market.

Myasthenia Gravis Treatment Market- Competitive Landscape:

Several organizations such as the government are counseling individuals regarding autoimmune diseases. E-commerce has become a vital tool for large and small businesses across the globe, due to the increase in the preference of consumers for online shopping as compared to traditional purchasing methods. Additionally, several animations through health apps to educate people regarding the usage of medications and myasthenia gravis have contributed toward the myasthenia gravis treatment market growth. Moreover, major market players have adopted strategic alliance, acquisition, product approval, expansion, and agreement as key developmental strategies to enhance the product portfolio of the myasthenia gravis treatment industry. For instance, in March 2021, Grifols a global healthcare company to improve the health and well-being of people worldwide announced to acquire GigaGen Inc. to boost a novel method to generate a broad range of immunoglobulins.

Recent Developments:

For instance, in April 2023, CSL Behring, a global biotechnology company, has received FDA approval for a 50mL/10gm prefilled syringe for Hizentra. CSL Behring offers a comprehensive variety of prefilled syringe sizes to satisfy the specific needs of persons suffering from Primary Immunodeficiency as well as Chronic Inflammatory Demyelinating Polyneuropathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET KEY PLAYERS

  • F.Hoffmann-La Roche AG
  • Alexion Pharmaceutical Inc.
  • Zydus Lifesciences Limited
  • Grifols SA
  • Shire plc
  • Kedrion
  • Avadel Pharmaceuticals, Plc.
  • Octapharma AG
  • Novartis
  • Bausch Health Companies Inc.
  • Pfizer, Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc.

GLOBALMYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • Thymectomy
  • Monoclonal Antibodies
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies
  • Chronic Immunomodulators
  • Others

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • Below 55 years
  • Above 55 years

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Drug store and retail pharmacies
  • Hospital pharmacies
  • Online providers

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Myasthenia Gravis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Myasthenia Gravis Treatment Market Snippet by Drug Class
    • 2.1.2. Myasthenia Gravis Treatment Market Snippet by Age Group
    • 2.1.3. Myasthenia Gravis Treatment Market Snippet by Distribution Channel
    • 2.1.4. Myasthenia Gravis Treatment Market Snippet by Country
    • 2.1.5. Myasthenia Gravis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Myasthenia Gravis Treatment Key Market Trends

  • 3.1. Myasthenia Gravis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Myasthenia Gravis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Myasthenia Gravis Treatment Market Opportunities
  • 3.4. Myasthenia Gravis Treatment Market Future Trends

4. Myasthenia Gravis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Myasthenia Gravis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Myasthenia Gravis Treatment Market Landscape

  • 6.1. Myasthenia Gravis Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Myasthenia Gravis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022&2030 (%)
    • 7.1.2. Thymectomy
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Cholinesterase Inhibitors
    • 7.1.5. Rapid Immunotherapies
    • 7.1.6. Chronic Immunomodulators
    • 7.1.7. Others

8. Myasthenia Gravis Treatment Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2022&2030 (%)
    • 8.1.2. Below 55 years
    • 8.1.3. Above 55 years

9. Myasthenia Gravis Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022&2030 (%)
    • 9.1.2. Drug store and retail pharmacies
    • 9.1.3. Hospital pharmacies
    • 9.1.4. Online providers

10. Myasthenia Gravis Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Myasthenia Gravis Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Myasthenia Gravis Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Myasthenia Gravis Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Myasthenia Gravis Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Myasthenia Gravis Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Myasthenia Gravis Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F.Hoffmann-La Roche AG
    • 11.2.2. Alexion Pharmaceutical Inc.
    • 11.2.3. Zydus Lifesciences Limited
    • 11.2.4. Grifols SA
    • 11.2.5. Shire plc
    • 11.2.6. Kedrion
    • 11.2.7. Avadel Pharmaceuticals, Plc.
    • 11.2.8. Octapharma AG
    • 11.2.9. Novartis
    • 11.2.10. Bausch Health Companies Inc.
    • 11.2.11. Pfizer, Inc.
    • 11.2.12. AbbVie Inc.
    • 11.2.13. GlaxoSmithKline Plc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Myasthenia Gravis Treatment Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Myasthenia Gravis Treatment Market, by Drug Class2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Age GroupSnapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Age Group
  • TABLE Global Myasthenia Gravis Treatment Market, by Age Group2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Myasthenia Gravis Treatment Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Myasthenia Gravis Treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Myasthenia Gravis Treatment Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022&2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Age Group segment market share analysis, 2022&2030
  • FIGURE Age Group segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022&2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022&2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Europe Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Latin America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Germany Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE India Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Brazil Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Saudi Arabia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)